Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Humacyte (NASDAQ:HUMA) and maintained a $15 price target.
October 10, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Humacyte and maintained a $15 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst suggests a positive outlook for Humacyte. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100